Dr. Jodie Jenkinson
Final presentation format
27 x 36 inches wall poster
I always wanted to design a beautiful graphic for people to get to know the drug development process. During my co-op time in a pharmaceutical company, I realize that this is a very streamlined but complicated process that few people know of. It's important for the public to understand what effort goes into developing vaccines and medications so that people can trust the product. A clear and engaging visual is needed to help people digest all the information related.
Shi, L., Sings, H. L., Bryan, J. T., Wang, B., Wang, Y., Mach, H., Kosinski, M., Washabaugh, M. W., Sitrin, R. Barr, E. (2006). GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side. Clinical Pharmacology & Therapeutics, 81(2), 259-264. doi:10.1038/sj.clpt.6100055
Cunningham, A. L., Garcon, N., Leo, O., Friedland, L. R., Strugnell, R., Laupèze, B., Doherty, M., & Stern, P. (2016). Vaccine development: From concept to early clinical testing. Vaccine, 34(52), 6655-6664. https://doi.org/10.1016/j.vaccine.2016.10.016.
Callaway, E., (2020, April 28). The race for coronavirus vaccines: a graphical guide. Nature News Feature. https://www.nature.com/articles/d41586-020-01221-y
Siddiqui, M. A. A., & Perry, C. M. (2006). Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs, 66(9), 1263-1271. https://doi.org/10.2165/00003495-200666090-00008
Villa, L. L., Costa, R. L., & Petta, C. A. et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology, 6(5), 271-278. https://doi.org/10.1016/S1470-2045(05)70101-7.
Buckland, B. C. (2005). The process development challenge for a new vaccine. Nature Medicine, 11, S16-S19. https://doi.org/10.1038/nm1218
Block, S. L., Brown, D. R., & Chatterjee, A. et al. (2010). Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine. The Pediatric Infectious Disease Journal, 29(2), 95-101. doi: 10.1097/INF.0b013e3181b77906.
Serdobova, I. & Kieny, MP. (2011). Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World. American Journal of Public Health, 96, 1554-1559. https://doi.org/10.2105/AJPH.2005.074583